Skip to main content
Top
Published in: European Spine Journal 8/2008

Open Access 01-08-2008 | Forum

Conducting a European multi-center trial: first experiences with the new EU Clinical Trials Directive from an academic perspective

Authors: Diyar Delawi, Wouter J. A. Dhert, F. Cumhur Oner

Published in: European Spine Journal | Issue 8/2008

Login to get access

Excerpt

In 2001 the European Union adopted the EU Clinical Trials Directive (2001/20/EC) as a framework for good management in trials of medicines [4]. Many concerns were expressed that this Directive would impede and inhibit publicly funded clinical trials [2, 7, 14]. …
Literature
1.
go back to reference Anonymous (2001) Is the university–industrial complex out of control? Nature 409(6817):119 Anonymous (2001) Is the university–industrial complex out of control? Nature 409(6817):119
2.
go back to reference Anonymous (2003) Who’s afraid of the European clinical trials Directive? Lancet 361(9376):2167 Anonymous (2003) Who’s afraid of the European clinical trials Directive? Lancet 361(9376):2167
3.
go back to reference Bodenheimer T (2000) Uneasy alliance—clinical investigators and the pharmaceutical industry. N Engl J Med 342(20):1539–1544CrossRefPubMed Bodenheimer T (2000) Uneasy alliance—clinical investigators and the pharmaceutical industry. N Engl J Med 342(20):1539–1544CrossRefPubMed
4.
go back to reference Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Communities 2001, L121:34–44 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Communities 2001, L121:34–44
5.
go back to reference Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282(15):1453–1457CrossRefPubMed Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL (1999) Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282(15):1453–1457CrossRefPubMed
6.
go back to reference Melander H, Hlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326(7400):1171–1173CrossRefPubMedPubMedCentral Melander H, Hlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326(7400):1171–1173CrossRefPubMedPubMedCentral
9.
go back to reference Remuzzi G, Schieppati A, Boissel JP, Garattini S, Horton R (2004) Independent clinical research in Europe. Lancet 364(9446):1723–1726CrossRefPubMed Remuzzi G, Schieppati A, Boissel JP, Garattini S, Horton R (2004) Independent clinical research in Europe. Lancet 364(9446):1723–1726CrossRefPubMed
10.
go back to reference Schieppati A, Remuzzi G, Garattini S (2001) Modulating the profit motive to meet needs of the less-developed world. Lancet 358(9293):1638–1641CrossRefPubMed Schieppati A, Remuzzi G, Garattini S (2001) Modulating the profit motive to meet needs of the less-developed world. Lancet 358(9293):1638–1641CrossRefPubMed
11.
go back to reference Stelfox HT, Chua G, O’Rourke K, Detsky AS (1998) Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338(2):101–106CrossRefPubMed Stelfox HT, Chua G, O’Rourke K, Detsky AS (1998) Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338(2):101–106CrossRefPubMed
12.
go back to reference Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359(9324):2188–2194CrossRefPubMed Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359(9324):2188–2194CrossRefPubMed
13.
go back to reference Vandendael K (2004) Challenges of The Clinical Trial Directive for non-commercial cinical trials. Newsletter of Federation of European Cancer Societies. 27-2-2004. Ref Type: Internet Communication Vandendael K (2004) Challenges of The Clinical Trial Directive for non-commercial cinical trials. Newsletter of Federation of European Cancer Societies. 27-2-2004. Ref Type: Internet Communication
Metadata
Title
Conducting a European multi-center trial: first experiences with the new EU Clinical Trials Directive from an academic perspective
Authors
Diyar Delawi
Wouter J. A. Dhert
F. Cumhur Oner
Publication date
01-08-2008
Publisher
Springer Berlin Heidelberg
Published in
European Spine Journal / Issue 8/2008
Print ISSN: 0940-6719
Electronic ISSN: 1432-0932
DOI
https://doi.org/10.1007/s00586-008-0699-5

Other articles of this Issue 8/2008

European Spine Journal 8/2008 Go to the issue